GeneDx WGS
GeneDx Holdings Corp. · Nasdaq · Services-Health Services
$64.69+3.11%close on Oct. 28, 2026 · volume 574K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 16, 2026 | Katherine Stueland CHIEF EXECUTIVE OFFICER, director | Sold | 10,501 | $97.61 $94.26-$99.00 | $1.03 million |
| Sept. 16, 2026 | Kevin Feeley CHIEF FINANCIAL OFFICER | Sold | 3,728 | $97.61 $94.26-$99.00 | $363,892 |
| Sept. 9, 2026 | Katherine Stueland CHIEF EXECUTIVE OFFICER, director | Sold | 3,692 | $84.22 | $310,932 |
| Sept. 9, 2026 | Kevin Feeley CHIEF FINANCIAL OFFICER | Sold | 1,285 | $84.22 | $108,220 |
| Sept. 1, 2026 | Kevin Feeley CHIEF FINANCIAL OFFICER | Sold | 372 | $83.84 | $31,188 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.